Vyriad
vyriad.com
Actively hiring
Cell & Gene Therapy
Health Care
Biotechnology
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$49.4M
6 rounds on record
Latest round
$25M
Series B · Dec 2025 · 9 mo ago
Team
51-200
employees, estimated range
Grants
$4.1M
4 grants · CORDIS
The money's age
Fresh money
9 months since the last round · not hiring
Momentum
35/100
in the news, fresh money
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
May 19
Launched Vyriad Launches G-Link: A Modular Platform Advancing T-Cell Targeted Lentiviral Vector Delivery for In Vivo and Ex Vivo Applications · businesswire.com
Dec 23, 2025
Raised a round Series B $25M · Pulse 2.0
Aug 24, 2021
Board appointment Vyriad, Inc. Appoints Harry Hoffman to its Board of Directors · Send2Press Newswire
Oct 30, 2019
Raised a round Venture round $24.4M · SEC Form D
Jul 18, 2018
Partnership Vyriad Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to Evaluate Oncolytic Virus, Voyager-V1, in Combination with Anti-PD-L… · PRNewswire
Funding rounds
Registers and programsofficial lists and records that name the company
| Legal entity | Vyriad, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Stephen Russell MD PhDExecutive Officer, DirectorSEC Form D
Kah-Whye Peng PhDExecutive OfficerSEC Form D
James HannonExecutive OfficerSEC Form D
Alice Bexon MDExecutive OfficerSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Metagenomi is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for…
Co-founded in 2017 by two pioneers in genome editing technology, Qihan Biotech has world-leading capabilities in multiplexable genome…
About Us We build the medicines we wish existed CPTx is a genetic medicines company redefining how we treat disease using immune-silent…
Ex-vivo gene therapy for phagocyte disorders. Somagenetix develops lentiviral HSC programs, starting with CGD—advancing safe, durable…
Capsida Biotherapeutics is an industry-leading gene therapy platform company creating a new class of targeted, non-invasive gene therapies…
Instant Quantification of genetic modifications for Cell and Gene Therapies.
News
Rochester's biomedical startup economy is growing. Finding the right workers is harder
In Rochester, new biomedical companies are growing out of Mayo Clinic. Local leaders want those companies to stay and grow in the community, but finding the right workers with the right skills is a bigger challenge.
Read more
Report
Vyriad Begins Phase 1 Clinical Trial for Lead In Vivo CAR T Cell Therapy VV169 Following FDA Acceptance of IND Application
Read more
Report
Vyriad Announces Strategic Leadership Changes to Drive Next Phase of Growth
ROCHESTER, Minn., June 23, 2026--Dr. Luke Russell appointed president, while CEO Dr. Stephen Russell transitions to chief scientific officer to spearhead scientific strategy.
Read more
Report
Vyriad Launches G-Link: A Modular Platform Advancing T-Cell Targeted Lentiviral Vector Delivery for In Vivo and Ex Vivo Applications
Read more
Report
Vyriad Launches G-Link: A Modular Platform Advancing T-Cell Targeted Lentiviral Vector Delivery for In Vivo and Ex Vivo Applications
Read more
Report
Vyriad: Final $25 Million Series B Tranche Closed To Advance In Vivo CAR T Candidate Into Clinic
Vyriad, a Rochester, Minnesota-based clinical-stage biotechnology company developing targeted genetic therapies, said it has closed a $25 million final tranche of its Series B financing, bringing the round's total to $85 million. The company said the addi
Read more
Report
Report
Vyriad targets 2026 clinical trial for experimental therapy VV169
VV169, an experimental cellular therapy that Vyriad is developing to treat myeloma, is expected to enter clinical testing in 2026.
Read more
Report
The "One Shot" Cure? How Vyriad's $85M Raise Could Replace Complex CAR-T Labs with a Single Injection
What You Should Know: - Vyriad, Inc. has secured the final $25M of its Series B financing, bringing the total round to $85M led by Mr. Harry Stine of Stine Seed Farms, Inc. - The
Read more
Report
Report
Show more news
People
Stephen Russell MD PhD
Executive Officer, Director
Kah-Whye Peng PhD
Executive Officer
James Hannon
Executive Officer
Alice Bexon MD
Executive Officer
Glen Barber
Director
Ahryon Cho
Director
Andrew Khoo
Director
Edwin Kania Jr.
Director
Nathan Stacy
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Rochester
United States
HQ
50-200 est. staff